Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)
Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
Mild/Moderate ( n =30) (absence of severe criteria)

Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)
Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
Mild/Moderate ( n =30) (absence of severe criteria)

Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)
Asthma (defined as severe) - (n=20)
CF (FEV1% predicted baseline <50%) - (n=20)
COPD (FEV1% predicted baseline <50%) - (n=20)
Idiopathic Pulmonary Fibrosis (n=20)

Spontaneously expectorated sputum, nasal lavage, brushings and nasal synthetic absorptive matrix (SAM) samples Venous blood (60mls) will be taken into Lithium Heparin tubes and PAXgene RNA tubes PAXgene tubes will be stored at -80C for further host genetic sequencing analysis. Further immunological analysis using yeast surface display for serum antibody profiling, single B cell sorting to generate monoclonal antibodies and ELISPOT to analyse CD4 and CD8 T cell ELISPOT to SARS CoV-2 peptide pools.

COVID-19

SARS-CoV 2

ARDS, Human

Immune System Disorder

Venesection, sputum nasal lavage and brushing if appropriate

Blood tests sputum, nasal lavage and brushing

PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort

Anti-viral cytokine protein concentration in blood samples by ELISA

Inflammatory cytokine protein concentration in sputum samples by ELISA

Inflammatory cytokine protein concentration in nasal lavage samples by ELISA

Inflammatory gene expression in upper airway respiratory epithelial cells by RNA sequencing.

Analysis of viral components recognized by the adaptive immune system

Cytokine protein concentration following PBMC stimulation to pathogen recognition receptor agonists by Elispot

Serum and plasma protein concentration of endothelial cell inflammation biomarkers by ELISA

aspergillosis/hypoxia

PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort

Најкомплетнија база лековитог биља подржана науком